公开(公告)号：WO2009082691A1

公开(公告)日：2009-07-02

申请号：PCT/US2008/087680

申请日：2008-12-19

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  UNIVERSITY OF WASHINGTON ,  PHILLIPS, Margaret ,  RATHOD, Pradipsinh, K. ,  GUJJAR, Ramesh ,  MARWAHA, Alka, S. ,  CHARMAN, Susan, A.

Inventor： PHILLIPS, Margaret ,  RATHOD, Pradipsinh, K. ,  GUJJAR, Ramesh ,  MARWAHA, Alka, S. ,  CHARMAN, Susan, A.

IPC: A01N43/54 ,  A01N43/90 ,  A61K31/519

CPC classification number: C07D487/04 ,  C07D473/34

Abstract: Compounds according to Formula (I), Formula (II), Formula (III), Formula (V), Formula (VI), or to Formula (VII), and pharmaceutical compositions of compounds that conform to Formula (IV) or (Formula VIII): where R 1 through R 33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.

Abstract translation: 根据式（I），式（II），式（III），式（V），式（VI）或式（VII））的化合物和符合式（IV）或（式 VIII）：其中R1至R33被规定，选择性地抑制恶性疟原虫二氢乳清酸脱氢酶。 因此，用于预防和治疗疟疾的方法附着于这些化合物，以及其药学上可接受的盐，溶剂合物，立体异构体，互变异构体和前药。

公开(公告)号：WO2008134086A1

公开(公告)日：2008-11-06

申请号：PCT/US2008/005617

申请日：2008-05-01

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  ZHONG, Guangming

Inventor： ZHONG, Guangming

IPC: C12Q1/02 ,  G01N33/52

CPC classification number: C12Q1/02 ,  G01N2333/295

Abstract: The present invention provides a method of diagnosing a Chlamydia infection in a subject, comprising contacting a sample from the subject with a substrate of chlamydial protease/proteasome-like activity factor (CPAF) under conditions whereby cleavage of the substrate can occur; and b) detecting cleavage of the substrate, thereby diagnosing a Chlamydia infection in the subject.

Abstract translation: 本发明提供了一种诊断受试者中衣原体感染的方法，包括：在可以发生底物裂解的条件下，使来自受试者的样品与衣原体蛋白酶/蛋白酶体样活性因子（CPAF）的底物接触; 和b）检测底物的裂解，从而诊断受试者的衣原体感染。

公开(公告)号：WO2006062826A3

公开(公告)日：2006-06-15

申请号：PCT/US2005/043686

申请日：2005-12-05

Applicant: NANOTECHNOLOGIES, INC. ,  BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  YACAMAN, Miguel, Jose ,  SCHRODER, Kurt, A. ,  MARTIN, Karl, Matthew ,  WILLAUER, Darrin, Lee

Inventor： YACAMAN, Miguel, Jose ,  SCHRODER, Kurt, A. ,  MARTIN, Karl, Matthew ,  WILLAUER, Darrin, Lee

IPC: A61K9/14

Abstract: This invention generally relates to use of novel nanomaterials comprised of metals in anti-viral applications. Such nanomaterials, for example, can be produced using a high power, pulsed plasma process, which plasma process, optionally, can be performed on the metal with a precursor (i.e., a gaseous precursor, such as acetylene or methane) when forming the unagglomerated nanomaterials. In embodiments of the invention, the metal is nanosilver. Optionally, the nanomaterials may also comprise carbon, including in the form of carbyne.

公开(公告)号：WO2005049793A3

公开(公告)日：2005-06-02

申请号：PCT/US2004/035643

申请日：2004-10-27

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  KAZHDAN, Irene

Inventor： KAZHDAN, Irene

IPC: C12P19/34

Abstract: The present invention provides a nucleic acid comprising a) a nucleotide sequence encoding one or more pro-apoptotic proteins, and b) a nucleotide sequence encoding one or more tumor-specific and/or tissue-specific promoters. Also provided is a method of treating cancer, comprising administering the compositions of this invention to a subject.

公开(公告)号：WO2005005465A2

公开(公告)日：2005-01-20

申请号：PCT/US2004/022734

申请日：2004-07-08

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  STACY, Sue ,  KRAIG, Ellen

Inventor： STACY, Sue ,  KRAIG, Ellen

IPC: C07K14/00

CPC classification number: A61K39/025 ,  A61K39/07 ,  A61K39/08 ,  A61K39/385 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/6031 ,  A61K2039/6037 ,  C07K2319/00

Abstract: The present invention provides a composition comprising a chimeric polypeptide comprising a recall antigen that reactivates memory T cells in a subject and a new antigen that activates naïve B cells in a subject and a composition comprising a nucleic acid encoding a chimeric polypeptide comprising a recall antigen that reactivates memory T cells in a subject and a new antigen that activates naïve B cells in a subject. Further provided are methods of eliciting an immune response, as well as treating and/or preventing disease in subjects in whom the ability to mount an immune response to a new antigen is impaired, by administering the compositions of this invention.

Abstract translation: 本发明提供包含嵌合多肽的组合物，所述嵌合多肽包含重新激活受试者中的记忆T细胞的回收抗原和激活受试者中初始B细胞的新抗原和包含编码包含召回抗原的嵌合多肽的核酸的组合物， 重新激活受试者中的记忆T细胞和激活受试者中初始B细胞的新抗原。 进一步提供的是通过施用本发明的组合物，引发免疫应答以及治疗和/或预防患有对新抗原产生免疫应答能力受损的受试者的疾病的方法。

公开(公告)号：WO2004065552A2

公开(公告)日：2004-08-05

申请号：PCT/US2004/001451

申请日：2004-01-21

Applicant: DUKE UNIVERSITY ,  BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM ,  NEWGARD, Christopher, B. ,  JENSEN, Mette, V. ,  SHERRY, A., Dean ,  BURGESS, Shawn, C.

Inventor： NEWGARD, Christopher, B. ,  JENSEN, Mette, V. ,  SHERRY, A., Dean ,  BURGESS, Shawn, C.

IPC: C12N

CPC classification number: C12N9/0006 ,  A61K35/12 ,  C12N5/0676 ,  C12N2510/00 ,  C12Y101/01028

Abstract: The present invention provides cells comprising an isolated nucleic acid encoding a novel lactate dehydrogenase (LDH) and/or the encoded LDH polypeptide. The invention further provides cells comprising an isolated nucleic acid encoding LDH, wherein the cell is capable of producing and secreting insulin. Also provided are methods of providing fuel-stimulated (e.g., glucose-stimulated) insulin secreting capability to a mammalian subject by implanting cells of the invention (e.g., in a semi-permeable membrane and/or an implantable device) into the subject. Further provided are devices comprising the cells of the invention. In particular embodiments, the device is an implantable device.

Abstract translation: 本发明提供包含编码新的乳酸脱氢酶（LDH）和/或编码的LDH多肽的分离的核酸的细胞。 本发明还提供包含编码LDH的分离的核酸的细胞，其中所述细胞能够产生和分泌胰岛素。 还提供了通过将本发明的细胞（例如，在半透膜和/或可植入装置中）植入受试者中来向哺乳动物受试者提供燃料刺激（例如，葡萄糖刺激的）胰岛素分泌能力的方法。 还提供了包括本发明的电池的装置。 在具体实施例中，该装置是可植入装置。

公开(公告)号：WO2003029431A3

公开(公告)日：2003-04-10

申请号：PCT/US2002/031655

申请日：2002-10-02

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

Inventor： BELCHER, Angela, M. ,  LEE, Seung-Wuk

IPC: C12Q1/70

Abstract: The present invention includes methods for producing nanocrystals of semiconductor material that have specific crystallographic features such as phase and alignment by using a self-assembling biological molecule that has been modified to possess an amino acid oligomer that is capable of specific binding to semi-conductor material. One form of the present invention is a method to construct ordered nanoparticles within the liquid crystal of the self-assembling biological molecule.

公开(公告)号：WO2003012048A3

公开(公告)日：2003-02-13

申请号：PCT/US2002/024121

申请日：2002-07-30

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM ,  BASEMAN, Joel, B. ,  ALVAREZ, Rene ,  KANNAN, Thirumalai, R.

Inventor： BASEMAN, Joel, B. ,  ALVAREZ, Rene ,  KANNAN, Thirumalai, R.

IPC: A61K39/155

Abstract: This application describes intracellular, cytoplasmic molecules that are translocated to the surface of a microorganism and participate in binding the microorganism to the surface of a host cell. Examples of such translocated molecules include glycerahdehyde 3-phosphate dehydrogenase, pyruvate dehydrogenase, and elongation factor-Tu. Regions oftranslocated molecules important for binding, as well as molecules which disrupt binding, are described. Antibodies directed to translocated molecules are also described.

公开(公告)号：WO2003003982A2

公开(公告)日：2003-01-16

申请号：PCT/US2002/021076

申请日：2002-07-02

Applicant: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

Inventor： KORGEL, Brian, A. ,  JOHNSTON, Keith, P.

IPC: A61K

CPC classification number: H01L33/24 ,  B82Y10/00 ,  B82Y30/00 ,  C30B7/00 ,  C30B29/605 ,  H01L21/02532 ,  H01L21/02601 ,  H01L21/02628 ,  H01L33/08 ,  H01L33/18 ,  H01L33/26 ,  H01L33/34 ,  H01L51/0595

Abstract: A method for the production of a robust, chemically stable, crystalline, passivated nanoparticle and composition containing the same, that emit light with high efficiencies and size-tunable and excitation energy tunable color. The methods include the thermal degradation of a precursor molecule in the presence of a capping agent at high temperature and elevated pressure. A particular composition prepared by the methods is a passivated silicon nanoparticle composition displaying discrete optical transitions.

Abstract translation: 一种生产稳定，化学稳定，结晶，钝化的纳米颗粒和含有该纳米颗粒的组合物的方法，其发射具有高效率和尺寸可调谐和激发能量可调颜色的光。 所述方法包括在高温和高压下在封端剂存在下前体分子的热降解。 通过该方法制备的特定组合物是显示离散光学跃迁的钝化硅纳米颗粒组合物。

公开(公告)号：WO1994002644A1

公开(公告)日：1994-02-03

申请号：PCT/US1993006716

申请日：1993-07-16

Applicant: APROGENEX, INC. ,  BAXTER DIAGNOSTICS INC. ,  BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM

Inventor： APROGENEX, INC. ,  BAXTER DIAGNOSTICS INC. ,  BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM ,  READING, Christopher, Lewis ,  CUBBAGE, Michael, Lee ,  HAYDOCK, Paul, Vincent ,  BRESSER, Joel ,  PRASHAD, Nagindra ,  BLICK, Mark ,  WEBER, William, Dugald ,  JU, Shyh, Chen ,  ASGARI, Morteza ,  COLVIN, David ,  JURTSHUK, Rebecca

IPC: C12Q01/68

CPC classification number: G01N33/58 ,  C12Q1/6841 ,  G01N33/5005 ,  G01N33/5306 ,  G01N33/56966 ,  G01N33/56983 ,  C12Q2531/143

Abstract: The process of detecting RNA molecules in situ using the 3SR amplification process, for example where the molecules are translocation-junction-spanning molecules in cells that have undergone chromosomal translocation. Also process modifications that enhance its effectiveness.

Abstract translation: 使用3SR扩增方法原位检测RNA分子的过程，例如其中分子是已经经历染色体易位的细胞中的易位结跨跨分子。 还可以处理增强其有效性的修改。